1015 related articles for article (PubMed ID: 16796890)
1. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
2. [Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding].
Gao ZQ; Lu FE; Dong H; Xu LJ; Wang KF; Zhou X
Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):101-4. PubMed ID: 15727694
[TBL] [Abstract][Full Text] [Related]
3. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
4. [Preventive and therapeutic effects of compound ginkgo extract in rats with nonalcoholic steatohepatitis induced by high-fat, high-fructose diet].
Yang Q; Zhao H; Zhou AZ; Lou ZH
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):852-858. PubMed ID: 27978932
[No Abstract] [Full Text] [Related]
5. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].
Zhao WH; Xiao JZ; Yang WY; Wang N; Wang X; Chen XP; Bu S
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3074-8. PubMed ID: 16324411
[TBL] [Abstract][Full Text] [Related]
8. [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats].
Chen LL; Deng XQ; Li NX
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1434-7. PubMed ID: 17785073
[TBL] [Abstract][Full Text] [Related]
9. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
10. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
Tipoe GL; Ho CT; Liong EC; Leung TM; Lau TY; Fung ML; Nanji AA
Histol Histopathol; 2009 Sep; 24(9):1161-9. PubMed ID: 19609863
[TBL] [Abstract][Full Text] [Related]
11. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease.
Duan XY; Zhao HP; Fan JG
J Dig Dis; 2010 Apr; 11(2):94-100. PubMed ID: 20402835
[TBL] [Abstract][Full Text] [Related]
12. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats.
Yin Y; Liu H; Zheng Z; Lu R; Jiang Z
Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
[TBL] [Abstract][Full Text] [Related]
14. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
15. [Role of JNK signal transduction pathway in nonalcoholic fatty liver disease].
Tan Y; Zhang JN; Chen JH; Wang LJ; Liu HX
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):821-5. PubMed ID: 19958640
[TBL] [Abstract][Full Text] [Related]
16. [Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease].
Liu YT; Li YQ; Wang YZ
Zhonghua Gan Zang Bing Za Zhi; 2016 Dec; 24(12):921-926. PubMed ID: 28073414
[No Abstract] [Full Text] [Related]
17. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
18. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
19. [Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].
Yin GL; Liang HY; Liang PP; Feng YN; Chen SW; Liu XY; Pan WC; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(7):1760-1769. PubMed ID: 37282950
[TBL] [Abstract][Full Text] [Related]
20. [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Chen XP; Yang WY; Bu S; Xiao JZ; Liu XL; Wang N; Zhao WH
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):280-3. PubMed ID: 15130413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
